Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. Its lead product candidate
(in fact just approved by FDA on the 07th of April) is intravenous form of meloxicam, a non-opioid that has completed Phase III clinical trials for the management of moderate to severe pain; and is in the Phase IIIb clinical trials in colorectal surgery and orthopedic surgery patients to assess opioid consumption, pain intensity, and length of hospital stay with associated pharmacoeconomic parameters. The company's early-stage product candidates includes RP1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; and RP2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and a reversal agent, as well as Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.
<https://finviz.com/quote.ashx?t=BXRX&ty=c&p=d&b=1> Received in February 2020 an NDA for their drug - ANJESO :
Présentation:
https://sec.report/Document/0001193125-20-043714/ ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing Full Commercial Launch Expected to Commence by June 2020 MALVERN, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that ANJESO™ (meloxicam) injection, the only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory drug (NSAID), is now available for ordering and delivery to customers. ANJESO was approved by the U.S. Food and Drug Administration (FDA) on February 20, 2020 and is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. <https://finance.yahoo.com/news/baudax-bio-announces-u-availability-120010729.html> We are diligently working to hire and train our field sales force and expect to execute the full ANJESO commercial launch by later in the 2nd quarter.” <https://finance.yahoo.com/news/baudax-bio-announces-u-availability-120010729.html> Article on Anjeso:
https://www.biospace.com/article/baudax-bio-wins-fda-approval-for-anjeso-a-non-opioid-pain-treatment/ ----------------
Raising capital for commercialization phase:
Cash (before warrants potential conversion at $3.25 and $4.59) :
Raised $25M on March 24th 2020
Had $17M in cash as of Dec 31st 2019
Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that, as part of its overall capital financing strategy to fund the Company and the upcoming commercial launch of ANJESO™, it has signed a non-binding term sheet with an undisclosed party for a secured term loan for up to $20 million in non-dilutive funding over the next 12 to 18 months.
Baudax expects to close this debt financing transaction in the next 4 to 8 weeks.
<https://sec.report/Document/0001193125-20-061374/> Shares outstanding:
<https://ycharts.com/companies/BXRX/shares_outstanding> -------------
Reports:
------------
https://sec.report/Ticker/BXRX
Insider buying:
-------------------
| CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.28 | 6,500 | 14,820 | 6,500 | Mar 30 08:00 PM |
| CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.44 | 25,000 | 61,000 | 52,782 | Mar 30 08:00 PM |
| Weisman Wayne | Director | Mar 26 | Buy | 2.29 | 10,000 | 22,900 | 40,582 | Mar 27 03:53 PM |
| ALTOMARI ALFRED | Director | Mar 26 | Buy | 2.34 | 5,000 | 11,700 | 33,382 | Mar 27 03:51 PM |
<https://finviz.com/quote.ashx?t=BXRX&ty=c&p=d&b=1> --------------
Analysts:
Janney starts Baudax Bio at buy; fair value estimate $12 https://biotuesdays.com/2019/11/22/janney-starts-baudax-bio-at-buy-fair-value-estimate-12/ Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong. She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”